- Lobbying
- Lobbying by Alvogen
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Eugenia Edwards Pierson | House Energy and Commerce Committee (2001-05) |
Kristine Blackwood | Deputy Dir. for Cong. Oversight, HHS (2010-15); Chief Counsel, Senate Aging (09-10); Investigative Counsel, House E&C (07-08); Attorney-Advisor, DOJ Leg Affairs (05-07); Healthcare Fraud Coordinator, DOJ (03-05); AUSA, Central District CA (94-03) |
Pari Mody | Intern, HHS Office of General Counsel Public Health (2013) |
Bobby McMillin | General Counsel, Senate Committee on Health, Education, Labor, & Pensions (HELP) (2015-2019); Counsel, Senate HELP Committee (2015); Counsel, Sen. Chambliss (2013-2015); Regional Rep., Sen. Chambliss (2012-2013); Press Intern, Sen. Chambliss (2007) |
Peter Duyshart | Program Support Student Trainee, Secretarial Internship Program, U.S. DOT (2020); Intern, Rep. Karen Bass (2015-2016); Extern, U.S. Attorneys Office, Central District of California (2015) |
Sonja Nesbit | Deputy Assistant Secretary of Legislation, U.S. Dept. of Health & Human Services (2013-2016); Deputy Staff Director, Ways and Means Committee, Subcommittee on Income Security and Family Support, U.S. House of Representatives (2002-2013) |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Registration
Issue(s) they said they’d lobby about: Issues related to domestic manufacturing of pharmaceuticals..
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate